Loading...
HomeMy WebLinkAboutDocumentation_Pension Public Safety_Tab 12-12_02/08/2016JAN -26-2016 TUE .10:27 -AN FAX NO. P. 01 CURRICULUM VITAE NRMTW, : PRESENT POSITION: 1998- DTOGFAPHY: Date of Birth: Place of 2irtl-i: Marital Status: Florida, License: California LiceT.se: ECFMG Certifjc,-:fte: DER Number: NPI Number: HOSPITAL PRIV:LEGES: 1990- 1990- 2000 - MEDICAL EDUCATION: Laszlo JOZsef Mate, M.D. Private Practice 824 TJS HWY 1, Ste. 230 Nortlpalm Beach, Florida 33408 561-626-5551 TAX 561-627-6545 Email.: drma'te@belIsouth.net December 3, 1951 Budapest, Hungary Married (3 children) 58250 � 44691 368-090-7 BM 1372436 1457351934 Palm. Reach Gardens Medical center St. Mary's Medical Center jupiter Medical Center 1972-78 Semnr:elweis Medical University Budape5t, >I angary 1978 M.D. Degree "Sunm,:', cum Laude" 'PROFESSIONAL EXPERIENCE: 1990-1998 ?rivate -Fractice Palm Beach Neurological. Group 5205 Greenwood Ave., Suite 200 West palm 5each, Florida 33407 JAN' 26 2016 Ip JAN -26-2016 TUE 1,0:27 'AM FAX NO. P. 02 Page 2 1988-1990 Fi.11.ow in, Pediatric Neurology Loma Linda University Medical Center Department of Pediatrics Divj.5ion of Child Neurology Loma Linda, 0� 92350 1987-1988 Fellow in ?ediatric Neurology University of California, San Diego nepartia8nt NellrclogY, K-815 San Diego, CA 92103-1990 1985-1587 Resident in Pediatrics University of Louisville Department Padiatrir-,s j,joLlisvi11e, KY 40292 1984-1965 clinical Instructor State Tiniver8ity of New York Downstate Medical Cente.r. 450 ClarksoTAvenue Brooklyn,, NY 11203 1983-1984 vigiting Instructor 1lniver5ity of Texas Medical Branch (�alves-tcn, TX 71550 1981-1982 clinical Physician ,lanas Hospital Budapest, Hungary 19 J8 -x.981 t;Jinical Physician postgraduate Medical School Budapest, Hungary MEMBERSHIP IN PROFESSIONAL SOCI'�TIE8: 1988- American Academy of Neurology 1989- Child Neurology Society 1990- 1995 American Society Of Neuroimaging 1992-2003 Florida Society of Neurology 2003- Florida Medical Association BOARD CERTIFICATICN-neurology with Special Q-U,7�lificat�01-1 in 1993 Child Neurology American Board of ?sychiatry and N8urology 1982 General Surgery Hung'ariar, Board of ME.,dical Specialties JAN -26-2016 TUE 10;27 AM FAX N0. P, 03 Page 3 BOARD ELIGIBILITY 1990 APPOINTMENTS: 1993-97 1997--98 1997-98 1997-99 1999-2000 1999- 2000-2001 2001-2003 2000- ADDIT70NAL INFORMATION: American Board of pediatrics Lcard of Directors ,andy Pines Hospital L)irector, Stroke Program t . Meryl s Hospital Director, Stroke Rehabilitation. "-t. Mary's Hospital Secretary Florida Society of nleurology president-elect Florida Society of Neuz:ology Expert Medical Advisor Florida Dept. Labor Division Of Ncrkers' c;umpensation President, Florida Society of Neurology Treasurer, Florida Society cf Neurology Medical Expert, Agency ,for fiealthcare Adm,i.nistration, State of Florida Besides 'Tngli.sh and Hungarian, I speak Spanish, Portuguese, Germ, an, French, Italian and some Russian. 2006 Investigator Training for Medical Ptesea.r ch Western Institutional Review Board University of Rochester School, of Medicine and Dentistry 2013 Research Investigator Training Florida Medical. Association. J'AN-26-2016 TUE 10:27 AM . ...... FAX NO. P. 04 Page 4 LIST OF ?OSLICATIONS His,t0jc)gjcaj changes in the operated Naas ,)s Mate L. Sziz-�,'Y Gy. stomachstomach with special referencereference -LO the carcinoma of the gastric stump. Mcrph Ig. Szemle 2Q:135-140, 1980 Joos A, Mate L, Szinay Gy, Papp J, ?opik E. Gastric cystic polyposis and early cancer Of the gastric stump. Acta Med Acad Sci Hung 38:341-346, 1981 Rozsa 1, Kan Me Tihanyi H, Mate L. Prcsta7-yclin (TG12) production of the portal vain wall in experimental portal hypertension. KiseL-I orvcstudcmany 33:344-346, 1981 3atorfi Jt Mate L. �kare complications of in'ca,-�cerated inguinal hernia. ory Hetilap 123:2230-2240, 1982 Ihasz Mr Balazs Me Mate L, Reei M. Malignant. melanoma of the anoroctum. Magy SebeSzet 35:260-266t 1982 Mate L, Greeley GHe rjaOmp,5cn JC. Failure of intraduodenal pancreatico anzymes to release pancreatic polypeptide in dogs. Gastroenterclogy 88:1176r 1984 Salcamoto Tr Mate L, Greelsy GRe Thompson JC. Effect of 71eurQtensin on gallbladder contracticn in dogs. Gastroenterology 86:1229', I984 T,<halil Tr Mate L, Greeley GH, Thompson JC. Decreased gallbladder responsiveness to CCK -8 in aged rabbits. Gastroenterology 86:1229, 1,984 Mate L, SeakamQto T, Thompson JC. The effe(--t c)f substance P on gallbladder =-tility in vivo and in vitro. Froc Scc Exp Biol Med 175:257, 1984 X�ialil T, Mate L, Greeley GH, Thc)mpsQn JC. Decreased gallbladder responsiveness to chole�--j I rstQkinin-octapeptide in aged rabbits in vitro. Dig Dis sci 29:42s, 1984 Mate L, Greeley GH, Thompson JC. The effect of two new peptides Qf the bombesin family On gastrointestinal f-uncticn in Clogs- 0i.g Dis, scie 29-52s, 1.984 Saj<am.oto T, Fuj imura Me Mate L, Greeley GH, Thompson JC. Characteristicsof (,,ont�rtactile kinetics of the gallbladder in 0 ja s t- :�in amino response to intravenous holecystQki -8 and intraduodenal acids. Dig Dis sci 29;lls, 1984 JAN -26-2016 TUE 10:27 AM FAX NO, P. 05 Page Publications, Continued Alwmarlc- a, Khalil T, Mate T,, Greeley GtI ThO-mPso'7� JC' GuL' hormones as incretin candidates, Surg forum 35-209-210, 19$4 Mate L, Greeley GE, Thompson JC. The effec ts Of opioids an the stimulated pancreatic secrc}tion and release of cholecystokinin and pa,ncreatic- Pclypepticie. Dig Dis Scie 29-959r 1.984 effect of Verapamil on bombesin stimulated L, Greeley' GH, Th(�)z�psQn JC- stimuIated pancreatic and gastric secretion and release of gastrin and cholecystokinin. Dig Dis Sci 29:960, 1985 Mate L, Greeley GH, Thompson JC. The role of pancreatic enzymes On pancreatic pclypeptide release, Dig Dis Sci 29:965, 1984 Sakamcto T, Fujimura M, Mjite L, Townsend CM, Greeley GH, Thompson JC. Fffect of vagotomy on neurotensin StizM-Ilated pancreatic secretion and pancreaticPcIYPeptidE� relea8e in dogs' Dig Dis Sci 29:965, 1984. MateL, Sakamoto T, Greely GK, Thompson JC. Fegi.aIation of gastric acid secretion by secretin and sej7ntanin. AM j Surgi 149-40-45, 198115 Doyle 1-1, Greeley GH, Mate L, Sakamoto T, Townsend CM, Thompson JC. NeurQtei7��in distribution in the canine gastrointestinal tract. Surgery 97:337-341, 1985 Lonovics J, Fimiara M, Lluis F, MatEt- L, VarrO V, 'Tho-mpsc)n JC- Chojecystokinin indi.�ced relaxatic�a Of the $phincter of Oddi. may partially be mediated by substance P. Gastroj�� .nterc].Qgy 88:1480, 1985 Sakai-ftotn T, Fujimllra M, mate L, Greejc-y GH, Th�)mp�cn JC. Effect of . emptying pancreatic protein secretion and vagotQmy on in responae to endogenous or exogenous CCK s,tjjjjj-jjation in dogs Gastroenterology 83:1.566, 1985 Mate L, Sakamc-to T, Greel.ey Gi-1, Thompson JC. Fffect of substa'nce P an contractions of the gallbladder. Surg Gynecol Obstet 163:1,63-166, 1986 JAN -26-2016 TUE 10:27 AM FAX NO, P. 06 Page 6 pui-)i,ications, continued Mate L, Greeley GI -1. opiQid peptides (endorphjrjs and enkephalins). in: ThoDpson JC, Greeley GV, ?,ayfcrd pl, Townsend CM, Jr ed. Gastrointestinal Endocrinology. McGraw Hill hook Co, New York 1987 pp. 346-354 Mate L, MacLc-,llan DG, Thompson 7C. Histamine. in: Thompson JC, Greeley GH, Fayford ?1, TownqenCD4. Jr. ed. Gastrointestinal FndccrinologY. McGaw Hill Book Cc, New YQrk 1997 pp. 361-364 Mate T, pQstcIi GJ, Thompson X. Serotonin, in: Thompson JC, Greeley GE, Rayford PL, Townsend CM, Jr ed. Gastrointestinal Endocrinology. McGraw Hill Book CO, New ycrk, 1967 pp. 365-311 Mate L, n8auchamP RD, Thompson JCI prostaglandins jr ed. in: Tliomp5cn JC, Greeley GH, Rayfoz�d PL, Townsend CM, G,,t.,,intc-stinaj, Endocrinology. McGraw Hill R00k CQ, New York 1987 pp. 372-379 Mate L, Doyle HR, Sakamotc T, Tcwnst--nd CM, Greeley GH, Thompson ic. The mechanism of the inhibitory action of neurotensin on pentagast�in-,stimj-jlated gastric secretion in dogs Surg Gynecol obstet 166:206-210, 1980 Mate L.: iozsef Matyas Balc- in: A$hw,�j s. ed Tounders c)f Child Neurology. ed. S. Ashwal, NQrmai� publishir�q, $an Franciscc 1990 pp. 410-415 2016-01-26 11:00 PBNC 561 6941360 >> 5616243278 CURRICULUM VITAE Michael M. Tuchman, M.D., FAAN BUSINESS ADDRESS: Palm Beach Neurological Center Advanced Research Consultants, Inc. 3365 Burris Read, Suite 203 Palm Beach Gardens, FL 33410 Phone: (561) 694-1010 Fax: (551) 282-5536 POSITION HELD: Palm Beach Neurological Center Neurologist/Psychiatrist Senior Clinical Investigator President / 1983 to present LANGUAGES SPOKEN: English; Spanish EDUCATION: Undergraduate: Tulane University, New Orleans, LA 1966-1970 B,A. Degree with Honors in Psychology Graduate: University of Florida School of Medicine, Gainesville, FL 1970-1974 M.D. Degree Post -Graduate: Internship/Residency: North Carolina Memorial Hospital, University of North Carolina, Chapel Hill, NC: Departments of Psychiatry & Neurology, 1974-77 Residency: Tulane Medical Center, New Orleans, LA, Department of Neurology, October 1, 1981- September 30, 1983 1976-77 Course in Electroencephalography; Department of Neurology, University of North Carolina, Chapel Hill, NC 11/14-11/16/01 Pharmacia — Investigator Support Initiative Training. Atlanta, GA. MEDICAL LICENSE: 1975 North Carolina #20354 4/20177 Florida #30451 MEDICAL CERTIFICATION: 1974 National Board of Medical Examiners, Parts I, 11, III SPECIALTY CERTIFICATION: 4/79 Psychiatry #19277, American Board of Psychiatry & Neurology 4/85 Neurology #27023, American Board of Psychiatry & Neurology 1986 Certified in Neuroimaging, American Society 4f Neuroimaging 1989 Certified in Neurosonology, American Society of Neuroimaging HONORS/AWARDS: 1965 Phi Beta Sigma - Honorary Freshman Scholastic Society 1968 Selection for Junior Year Abroad - Tulane University 1970 Cum Laude, Phi Beta Kappa P 3/13 2016-01-26 11:00 PBNC 561 6941360 >> 5616243278 P 4/13 Page 2 of 11 HONORSIAWARDS (cont,j: 1970 Hoffman Award - Outstanding Undergraduate Psychology Major 1971-72 Student American Medical Association; National Committee Chairman for Human Sexuality 1973 Teaching Award; Medical Gass of 1976 for Neuroscience Teaching to First Year Medical Students - University of Florida 1973 E=xchange Student; London Psychiatric Institute, Maudsley Hospital, London, England 1988 Director, Neurology Update for Practicing Physicians at Jupiter Medical Center, Jupiter, FL 1989 Vice President, Florida Society of Neurology 1990-91 President, Florida Society of Neurology 1993 Fellow, American Academy of Neurology MEMBERSHIPS: American Academy of Neurology Florida Society of Neurology American Society of Neuroimaging American Headache Society International Stroke Society Royal Society of Neurology CLINICAL EXPERIENCE: 1977-81 Private Practice in Psychiatry & Neuropsychiatry, Burlington, NC 1977-81 Director Electroencephalography Lab, Memorial Hospital of Alamance County, Burlington, NC 1983 to Private Practice in Neurology & Psychiatry, Advanced Research Consultants, Inc., President, Present Principal Investigator, Palm Beach Gardens, FL HOSPITAL APPOINTMENT$: 1983 Jupiter Medical Center TEACHING EXPERIENCE: 1973 Assistant in Neuroscience to 151 Year Medical Students - Neuroscience Course, University of Florida Medical School, 1976 Lecturer in "The Psychological Assessment of Patients" to 3rd Year Medical Students, University of North Carolina School of Medicine. 1976 Lecturer in Psychopharmacology to 3`d Year Medical Students, University of North Carolina School of Medicine. 1974-76 Supervisor of 3rd Year Medical Students in Psychiatry, University of North Carolina School of Medicine. 1976 Chief Resident, Psychopharmacology Clinic, Department of Psychiatry, University of North Carolina, Chapel Hill, NC, 1970 North Carolina Neuropsychiatric Associated Invited Panelist, Section on Clinical Psychopharmacology. 1978-79 Psychopharmacology Course to Clinical Staff, Memorial Hospital, Alamance County, NC. 1982 Neurology Course to 3'd Year Medical Students at Tulane University, 1989 Neurology Update to ICU Nurses at Palm Beach Gardens Medical Center. 1989 Headache Treatment Strategies to Jupiter Hospital Medical Staff. 1991 Headache and Gerebrovascular Disease to Jupiter Hospital Medical Staff. 1992 Alzheimer's and the Dementias to Jupiter Hospital Medical Staff_ 1992 Guest Lecturer to the Annual Review Course - "Topics in Internal Medicine", Update on Dementia, held in (Orlando, Walt Disney World, FL, 1992-93 Guest Lecturer in Migraine to Florida and Georgia Medical Societies. 1993 Migraine -Topics in Neurology, Pinellas County Medical Society. 1997 Guest Lecturer on Alzheimer's disease, "Understanding the Language of Dementia", for the 3`d Annual Alzheimer's Disease Educational Conference in West Palm Beach, FL. 1997 Guest Lecturer on Alzheimer's Disease Update, Boca Raton, FL. 1997 Guest Lecturer on "Strategies for Evaluation, Prevention & Treatment of Alzheimer's Disease", San Juan, PR, 1997 Guest lecturer on Stages of Alzheimer's Disease for Alzheimer's Community Care Annual Educational Conference, West Palm t3each, FL, 2016-01-26 11:00 PBNC 561 6941360 >> 5616243278 P 5/13 Page 3 of 11 TEACHING EXPI=RIENCE, (cont, 1997 west Lecturer on Progress & Perspectives on Intervention and Care for Alzheimer$ Disease, Held at Hyatt Regency, Miami, FL. 1997 west Lecturer on "Stroke Awareness & Prevention", Jupiter Hospital, Jupiter, FL. 1998 Invited Panelist, Stroke Conference, Texas Medical Center, Houston, TX, 1998 Guest Lecturer on "Migraine Treatment", Mexico City, MX, 1998 Guest Lecturer on "Migraine Treatment", Montraeu, MX. 1998 Guest Lecturer on Migraine Topics, Bogota, Columbia. 1998 Faculty Chairman, Maxalt Investigator Meeting, Merck, Atlanta, GA. 1998 Guest Lecturer on Alzheimer's Disease, San Juan, PR. 1999 Guest Lecturer on Alzheimer's Disease, San Juan, PR. Community Care Annual Educational Conference, West Palm Beach, FL. 2000 Guest Lecturer on Alzheimer's Disease for Alzheimer's Community Care Annual Educational Conference, West Palm Beach, FL. 2000 Guest Lecturer on Migraines, Palm Beach, FL. 2009 Guest Lecturer on Alzheimer's Disease for Alzheimer's Community Gare Annual Educational Conference, West Palm Beach, FL 2010 Guest Lecturer on Alzheimer's Disease for Alzheimer's Community Care Annual Educational Conference, West Palm Beach, FL 2011 Guest Lecturer on Alzheimer's Disease for Alzheimer's Community Care Annual Education Conference, West Palm Beach, FL, 2012 Guest Lecturer on Alzheimer's Disease. "Memory Loss, Is it Dementia or Depression?" Alzheimer's Community Care Annual Education Conference, West Palm Beach FI, 2013 Keynote Speaker on Alzheimer's Disease at the Fearless Caregiver Conference, Palm Beach Gardens, FL, 2013 Guest Lecturer on Alzheimer's Disease; Early Diagnosis, Treatment and Research options. Alzheimer's Community Care Annual Education Conference, 2013 Guest Lecturer on Parkinson's Disease, Parkinson's Education Network, Jupiter, FL_ 2014 Guest Lecturer on Prodromal AD; Advancements in Diagnosis and Treatment. Alzheimer's Community Care Annual Education Conference. PUBLICATIONS & PRESENTATIONS: 1970 "Motivational Factors in Hypnotic Susceptibility" — an honor thesis, Tulane University, Department of Psychology. 1973 "Pharmacology of the Monoamine Neurotransmitters" W a review of the literature presented to the Grand Rounds in Pharmacology, University of Florida School of Medicine, 1975 "Neuropharmacological Aspects of Huntington's Chorea, Parkinson's Disease, Tardive Dyskinesla & Schizophrenia" -- presented at Grand Rounds, Department of Psychiatry, University of North Carolina, Dix Hospital Program, 1975 "High vs. Low Dose Doxepin in Depressed Patients; A Controlled Study", Excerpta Medica, 1975. 1976 "Treatment of Dextroamphetamine; First Reported Case" — The Journal of Nervous & Mental Disease, Vol, 162, No. 5, 1976. 1977 "Anorexia Nervosa, A Neuropsychiatric Syndrome" — Neurology Grand Rounds, University of North Carolina Hospital School of Medicine. 1984 "Panic Attacks and Psychomotor Seizures Associated with a Right Temporal Lobe Arteriovenous Malformation". 1985 "Headache: Don't Let it Spoil Your Life", DONDE, Vol. 6, No, 2, 1985. 1996 "Randomized Double -Blind, Multicenter Study Comparing Midodrine with Placebo in Neurogenic Orthostatic Hypotension", 1996 "Acute Treatment of Migraine with Dihydroergotamine Nasal Spray". 1997 "Efficacy of Midodrine vs. Placebo in Neurogenic Orthostatic Hypotension", a Randomized, Double -Blind, Multicenter Study, JAMA, 4/2!97, Vol. 277, No. 13. 1997 "Lubeluzole Treatment of Acute Ischemic Stroke", Stroke, Vol. 28, No, 12. 1998 "Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence, A Placebo -Controlled, Outpatient Study". Headache, Vol. 38, No. 4. 2016-01-26 11:00 PBNC 561 6941360 >> 5616243278 P 6/13 Page 4 of 11 PUBLICATIONS & PRESENTATIONS (cant,): 1998 Maximizing migraine relief with zolmitriptan: preliminary data from an open study with >25,000 treated attacks, American Academy of Neurology Annual Meeting. 2000 LU25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology 2000; 54:421-426, 2000 I-evetiracetam for Partial Seizures. Results of a double-blind, randomized clinical trial. Neurology. Vol. 55, No. 2, July 2000. 2002 Significant 1 -hour pain-free rates with zolmitriptan 2.5 mg orally disintegrating tablet in Treatment of migraine: results of a large double-blind, placebo-controlled trial. European Journal of Neurology, (Suppl, 2), 107-164. 2002 '"Sumatriptan is Effective In Migraine Presenting As `Sinus Headache" Results of a Randomized, Double -Blind, Placebo -Controlled Study. Poster Presentation, Diamond Headache Meeting, Orlando, Florida, Glaxo SmithKline. 2003 "Sumatriptan is Effective in Migraine Presenting As 'Sinus Headache": Results of a Randomized, Double -Blind, Placebo- Controlled Study. Poster Presentation, American Academy of Neurology Meeting, April 2, 2003, Honolulu, Hawaii, Glaxo ;SmithKline, 2003 "Oral Zolmitriptan is Efficacious as Acute Therapy for Pure Menstrual Migraine": Results of a Second Large Prospective, Multicenter, Placebo -Controlled Trial, Platform Presentation, American Academy of Neurology Meeting, April 2QQ3, Honolulu, Hawaii, Astra Zeneca 2003 "A Single One -Hour Application of High -Concentration Capsaicin Patches Leads to Four Weeks of Pain Relief in Postherpetic Neuralgia Patients." Platform Presentation, American Academy of Neurology, April 2003, Honolulu, Hawaii, Neurogesx, 2003 "Pregabalin for the Treatment of Postherpetic Neuralgia", A randomized, Placebo -Controlled Trial, April (2 of 2) 2003, Neurology 60, 2004 "Pregabalin for the Treatment of Painful Diabetic Peripheral Neuropathy: A Double-blind, Placebo- controlled Trial", Pain, Volume 110, Issue 3, Pages 628-638. 2005 "Oral Zolmitriptan 2.5 mg Demonstrates High Efficacy and Good Tolerability in the Prophylactic Treatment of Menstrual Migraine Headaches" Platform Presentation, 47"' Annual Scientific meeting of the American headache Society. June 23-26, 2005, Philadelphia, PA. 2006 "High -Dose Atorvastatin after Stroke or Transient Ischemic Attack" The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, The New England Journal of Medicine, Vol, 355 No. 6, August 10, 2006, Pages 549-559. 2006 Efficacy and Tolerability of Zolmitriptan Oral Tablet in the Acute Treatment of Menstrual Migraine et al. CNS Drugs 2006: 20 (12); 1019-1026, 2006 Vinik Al et al„ Lamotrigine for the treatment of pain associated with diabetic, Pain (2006), doi:10,10'16/j , pain. 2006.09.040 2006 Soren H, Sindrup, Troels S. Jensen, Are sodium channel blockers useless in peripheral neuropathic pain? Pain(2006),doi:10,1016/j.pain.2006.0.010 2007 Poster presentation Q Annual Meeting for the American Academy of Neurology. May 2007, P05.025, Zolmitriptan is Effective and Well Tolerated in Both Acute and Prophylactic Treatment of Menstrual Migraine. Michael Tuchman, Ugochinyere Emeribe 2007 Vinik Al, Tuchman M, Safirstein B, et al. Lamotrigine for the treatment of pain associated with diabetic neuropathy: results of two randomized double-blind, placebo-controlled studies, Pain 2007; 128:969-179 2007 Treatment with Pregabalin for relief of Fibromyalgia: Analysis of two -double-blind, randomized, Placebo -Controlled trials (1056 Lift and 1077 Relief Studies), ACNP 92000 American College of Nurse Practitioners- 2007 National Clinical Conference. Abstract and poster presentation, 2008 Poster Presentation @ American Academy of Neurology. April 2008 Pregabalin and Central Sensitization in Chronic Pain Syndromes: Evidence Supporting a Common Pharmacologic Effect. Michael Tuchman, Jannette Barrett, Edith Durso-DeCruz, Kevin Murphy 2008 Randomized controlled trial of an oral CGRP receptor antagonist, MK -0974, in acute treatment of Migraine T.W. Ho, L.K. Mannix, X Pan, C. Assaid, C. Furtek, C.J. Jones, C.R. Lines, and A.M. Rapoport, On behalf of the MK -0974 Protocol 004 study group 2008 Oral Zolmitriptan in the Short- Term Prevention of Menstrual Migraine, A randomized, placebo- controlled study. CNS Drugs 2008; 22(10)1 2016-01-26 11:01 PBNC 561 6941360 » 5616243278 P 7/13 Page 5 of 11 PUBLICATIONS a PRESENTATIONS (cont.): 2008 Is the analgesic effect of Pregabalin related to the alteration of central sensitization? EFNS (2008) European Federation of Neurological Societies- 12th Congress. Abstract and poster presentation. 2010 Poster Presentation @ American Academy of Neurology. April 2010, A Randomized, Double -Blind, Placebo-Contralled, Multicenter, Phase 2 Trial of Intradermal Onabotullnumtoxin A injections in the Treatment of Post Herpetic Neuralgia (PHN)" 2010 Poster presentation @ APS meeting Baltimore, MD, April 2010. Duration of Treatment Response to NGX-4010, A High Concentration Capsaicin Patch, in Patients with Post herpetic Neuralgia (PHN). 2010 "Central Sensitization and Ca (V) alpha (2) delta Ligands in Chronic Pain Syndromes: Pathologic Processes and Pharmacologic Effect, J Pain. 2010 May, 2012 'Burden of Spinal Cord Injury -Related Neuropathic Pain (SCI -Nei?) in the US: BEAT Neuropathic Pain Observational Study. AAPM (2012) American Academy of Pain M2nagement-23" Annual Clinical Meeting. Abstract presented, 2012 Post-traumatic/ Post -surgical -related Neurapathic Pain in the US. AAPM (2012) American Academy of Pain Management -23" Annual Clinical Meeting. Abstract/ Poster presented. 2012 Characteristics of Subjects with Chronic Low Back Pain Related Neuropathic Pain in the US: BEAT Neuropathic Pain Observational Study, 2012 Characteristics of Subjects with Painful Diabetic Neuropathy (PDN) in the US: BEAT Neuropathic Pain Observational Study, ANA (2012) American Neurological Association- 137"' Annual Meeting, Abstract and poster presented. 2012 Characteristics of subjects with Painful Peripheral Neuropathy with Small Fiber Involvement in the United States: BEAT Neuropathic Pain Observational Study. ASRA (2012) American Society of Regional Anesthesia, and Pain Medicine. Poster presented. 2013 "Burden of spinal cord injury -related neuropathic pain in the United States: retrospective chart review and cross-sectional survey. Spinal Cord advance publication, 16 April 2013. 2013 Opioid and Antiepileptic [Drug utilization Among Patients with Chronic Neuropathic Pain Conditions. ISPOR (2013) International Society for Pharmacoeconomics and Outcomes Research- 18`h International Meeting Abstract and Poster presented 2013 Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the U$: results from a retrospective chart review and cross sectional survey. 2013 Economic and humanistic burden of post -trauma and post-surgical neuropathic pain among adultg in the United States. Journal of Pain Research. 2014 To characterize the burden of idiopathic painful peripheral neuropathy with small fiber involvement (idiopathic SFN) by pain severity in the US, Journal of Medical Economics 2014 "Pain Severity and the Economic Burden of Neuropathic Pain in the United States: BEAT Neuropathic Pain Observational Study ClinicoEconomics and Outcomes Research 2014 "Health status, function, productivity, and costs among individuals painful peripheral neuropathy with small involvement in the United States: results from a retrospective chart review and cross- sectional survey". Journal of Medical Economics RESEARCH/CLINICAL PHARMACOLOGY, 1970 Tuiane University - Motivational Factor in Hypnosis. 1973 University of Florida - High vs, Low Dosage Levels in Tricyclic Antidepressants. Doxepin, Pfizer Labs, Phase IV. 1974 University of North Carolina -Amphetamines in OBS, 1976 University of North Carolina -Anorexia Nervosa & Temporal Lobe Epilepsy, 1979 Inderal, for Anxiety ;states NC, Ayerst Labs, Phaselll. 1982 Epilepsy & Panic Attacks, 1990 Sumatriptan, for Migraine, Glaxo Labs, Phase III, 1991 Sumatriptan, Protocol $2B-308E,Glaxo Labs. 1991 Cognex, for Alzheimer's Disease, Parke -Davis Labs, Phase IV. 1902 DHE, for the Emergency Management of Episodic Vascular Headache, Sandoz Labs, Phase IV. 1992 Clopidogrel, for Patients at Risk of Ischemic Events, Sterling -Winthrop Labs, Phase III. 1993 Fluvoxamine, Protocol M/2316/00013, for Panic Disorder, 1993 Tiagabine, M92-813, for Epilepsy, Abbott Laboratories. 1993 Mentene, for Alzheimer's Disease, Upjohn, Phase III. 2016-01-26 11:01 PBNC 561 6941360 >> 5616243278 P 8/13 Page 6 of 11 RESEARCH/CLINICAL PHARMACOLOGY (cant, , 1993 Sumatriptan, Protocol S28-316, Glaxo. 1993 Nudodiuril in the Treatment of Orthostatic Hypotension, Protocol 20,762-320. 1993 Pramipexole, for Early Onset Parkinson's Disease, Upjohn, Phase 111. 1993 Sumatriptan, Protocol S213-3401341. 1994 MK -462, Protocol 014, for Migraines, Merck, Phase NI. 1954 Sumatriptan Nasal Spray, Protocol 82B-342, for Migraines, Glaxo, Phase III, 1994 UCB L059, Protocol RPCE94A1403, for Add-on Treatment in Epileptic Patients with Partial Onset Seizures, UCB S.A., Pharma Sector, Phase III. 1994 Modafinil, Protocol C1538A/304 NA/US, for Narcolepsy, Cephalon, Inc„ Phase III. 1994 311090, Protocol 136-017, for Migraines, Burroughs Wellcome, Phase 111. 1994 311C90, Protocol 136-015, for Migraines, Burroughs Wellcome, Phase 111. 1994 Migramist Nasal Spray, Protocol DHE #454, for Migraines, Sandoz, Phase I11 -B. 1994 MKA62, Protocol MK -462, for Migraines, Merck, Phase 111. 1995 CNS -1102, Protocol CNS1102, for Acute Cerebral Ischemia, Cambridge Neuroscience, Phase Il, 1995 Eldepryl, Protocol 59402-E100-94, for Parkinson's disease, Somerset, Phase 11113. 1995 MK -0462, Protocol MK -0462, for Migraines, Merck, Phase Ill. 1995 Naratriptan, Protocol S2WA3001, for Migraines, Glaxo, Phase 111, 1995 Naratriptan, Protocol 82WA3003, for Migraines, Glaxo, Phase Ill. 1995 Stadol Nasal Spray, Protocol CN102-022, for Acute Migraines, Bristol-Myers Squibb, Phase IIIB. 1995 Tiagabine, Protocol M92-825, for Seizures, Abbott, Phase III, 1995 Tiagabine, protocol M91-604, for Seizures, Abbott, Phase 111, 1995 Sabril, Protocol VGPRO101, for the Management of Patients with Non -Refractory Complex Partial Seizures, Hoechst Marion Roussel, Phase III. 1995 Stadol Nasal Spray v, Acetaminophen & Codeine Phosphate, Protocol CN102-020, for Acute Migraine Headache Pain, Bristol-Myers Squibb, Phase 1118. 1996 Lubeluzole, Protocol LUB-INT-9, for Acute Cerebral Ischemia, Janssen Pharmaceutical, Phase II. 1996 Metrifonate, Protocol D95-018, for Patients with Probable Alzheimer's Disease, 1996 MK -0462 Rapidisc, Protocol MK -0462, for Migraines, Merck, Phase III, 1996 Alnitidan, Protocol ALN -INT -16, for Migraines, Janssen, Phase III, 1995 Gerestat, Protocol 534.11, for Ischemic Stroke, Boehringer Ingelheim, Phase Ill. 1996 Lubeluzole, Protocol LUB-INT-13, for Ischemic Stroke, Janssen, Phase III, 1996 Tacrine, Protocol 970-68-22, for Dementia of the Alzheimer's Type, Parke Davis, 1996 Milameline, Protocol 979-15, for Probable Alzheimer's Disease, Parke Davis. 1996 Metrifonate, Protocol X-95-018 - Extension to Protocol D95-018, for Probable Alzheimer's Disease, Parke Davis_ 1996 Metrifonate, Protocol U96-001, for Probable Alzheimer's Disease, Parke Davis. 1996 UCB L059, Protocol RPCE94A1403, for the Add-on Treatment in Epileptic Patients with Partial Onset Seizures, UCB S.A., Pharma Sector, Phase 111, 1996 Maximm, Protocol 136-043, for Acute Migraine Headache Pain, Zeneca Pharmaceuticals, Phase Ill- 1996 IL1996 MK -462, Protocol 022-00- Extension Portion, for Acute Migraine Pain, Merck, Phase 111, 1996 Rizatriptan, Protocol 046-00, for Migraine Pain. Merck, Phase 111. 1996 UCB-1_059, Protocol RPCE-94J-1403, for Epileptic Patients with Partial (Onset Seizures, UCB-SA, Pharma Sector, Phase 111. 1997 L-754-030, Protocol 010-00, for Post herpetic Neuralgia, Merck, Phase IIA. 1997 Rizatriptan/Rapidisc, Protocol 049-00, for Acute Migraine Pain, Merck, Phase III. 1997 Gabapentin, Protocol 945-213, for Newly Diagnosed Patients with Partial Epilepsy, Parke }Davis, Phase III, 1997 Alniditan S.C., Protocol ALN -USA -18, for Migraine Attacks, Janssen, Phase III. 1997 Alniditan S.C., Protocol ALN -INT -17, for Migraines, Janssen, Phase III. 1997 LU25-09, Protocol 96208, for Alzheimer's Disease, H. Lundbeck AIS, Phase Ill, 1997 Lazabemide, Protocol PDL -1000P, for Alzheimer's Disease, Protodigm, Phase 111. 1997 Naratriptan, Protocol S2WA4002, for Migraine in Subjects Who Do Not Respond to Oral Sumatriptan, Glaxo Wellcome, Phase 111. 1997 Metrifonate, Protocol D97-019, for Alzheimer's Disease, Bayer, Phase 111. 1997 LU25-108, Protocol 97202, fQr Alzheimer's Disease, H. Lundbeck A/$, Phase Ill. 2016-01-26 11:01 PBNC 561 6941360 >> 5616243278 P 9/13 Page 7 of 11 RESEARCHICLINICAL PHARMACOLOGY cont. 1997 Zydis Selegiline, Protocol MEL/97/025, as an Adjunct in the Management of Parkinsonian Patients Being Treated with Levodopa; M,0,3„ Harris, Phase ill. 1997 Zydis Selegiline, Protocol Z/SEU97/027, as an Adjunct In the Management of Parkinsonian Patients Being Treated with Levodopa, M.D.S,, Harris, Phase III, 1997 Sertraline, Protocol R-0552, for Major Depression in Elderly Patients, Pfizer, Phase IV. 1998 4991W93, Protocol CIAA2001, Acute Treatment of Migraine Headache, Glaxo Wellcome, Phase 11, 1998 Idebenone, Protocol PNFP-004, for Probable Alzheimer's Disease, Takeda America, Phase III 1998 Idebenone Added to Treatment with Donepezii, Protocol PNFP-007, for Patients with Probable Alzheimer's Disease, Takeda America, Phase III, 1998 Pregabalin, Protocol 1008-014-026, for Painful Diabetic Peripheral Neuropathy, Parke -Davis, Phase Il/111, 1998 Pregabalin, Protocol 1008.015-026, for Painful Diabetic Neuropathy, Parke -Davis, Phase 11/111, 1998 Pregabalin, Protocol 1008-030-130, for Post herpetic Neuralgia, Parke -Davis, Phase 111111, 1998 Pregabalin, Protocol 1008-033-130, for Post herpetic Neuralgia, Parke -Davis, Phase 11/111. 1998 Lazabemide, Protocol PDL -1015P, for Alzheimer's Disease, Protodigm, Phase 111. 1999 MKO9660911-00, for Slowing the Progression of the Symptoms of Alzheimer's Disease, Merck, Phase Ill. 1999 SPARCL, Protocol 981-124,073, for Prevention of Stroke, Parke -Davis, Phase III. 1999 Pregabalin, Protocol 1008-105-538, for Pain Related to Fibromyalgia, Parke -Davis, Phase 111, 1999 Pregabalin, Protocol 1008-033 Open Label Extension, for Pain Related to Fibromyalgia, Parke Davis, Phase II/111. 1999 Neotrofin, Protocol 082-99-003, for Probable Alzheimer's Disease of Mild to Moderate Severity, NeoTherapeutics, Phase Iib, 1999 MAX47$, Protocol 061-00, for Migraine, Merck, Phase IV. 1999 Zolmitriptan, Protocol 311CUS/0003, for the Prophylactic Treatment of Menstrual Migraine Headache, AstraZeneca, Phase I/Il. 1999 MKO-242, Protocol MKC-242-A01, for Depression, Mitsubishi, Phase 11, 1999 MKC-242, Protocol MKC-242-A02 - A 4 -Month, Double -Blind, Extension to study MKC/242-A01, for Major Depressive Disorder, Mitsubishi, Phase 11. 1999 MKC-242, a 1 -Month Follow-up after Termination of Study MKC-2424A01, for Major Depressive Disorder. 2000 Apomorphine, Protocol AP0401, for the Treatment of Wearing Off Time Associated with Parkinson's Disease, Mylan Pharmaceuticals, Phase III. 2000 Pregabalin, Protocol 1008-127-026, for Post herpetic Neuralgia, Parke -Davis, Phase II/III. 2000 Pregabalin, Protocol 1008-134-026, for Post herpetic Neuralgia, Parke -Davis, Phase IIPII. 2000 Pregabalin, Protocol 1008-131-104, for Painful Diabetic Peripheral Neuropathy, Parke -Davis, Phase Il/ill. 2000 Pregabalin, Protocol 1008-131-104, for Painful Diabetic Peripheral Neuropathy, Parke -Davis, Phase 11/III 2000 MK -09661 Protocol 126-01, for slowing the Progression of Probable Alzheimer's Disease, Merck, Phase Ill, 2000 MT100, Protocol MT100-304, for Acute Migraine Attacks, Pozen, Phase Ill. 2000 Sumatriptan, Protocol SUM40275, for the Treatment of Mild Pain Phase of Migraine Attacks, Glaxo Wellcome, Phase III. 2000 Pregabalin, Protocol 1008-090-020, for Anxiety in the Elderly, Pfizer, Phase 11. 2000 CJ -15-161, Protocol A295-1007, for Adult Patients with Postherpetic Neuralgia, Pfizer, Phase ll. 2000 Pregabalin, Protocol 1008-132-101, for Post herpetic Neuralgia, Parke -Davis, Phase Il/ill. 2000 Pregabalin, Protocol 1008-174-101, for Post herpefic Neuralgia, Parke -Davis, Phase it/III. 2000 Zolmitriptan, 2.5 mg orally Disintegrating Tablet, Protocol 311CUS/0014, for Migraine, AstraZeneca, Phase 11- 2001 Zolmitriptan, 5 mg Orally Disintegrating Tablet, Protocol 311CUS/0015, for Migraine, AstraZeneca, Phase 11. 2001 MT400, Protocol MT400-204, for Acute Migraine Attacks, Pozen, Phase IIL 2001 Neotrofin, Protocol 082-2001-001, for Probable Alzheimer's Disease of Mild to Moderate Severity, NeoTherapeutics, Phase Ill. 2016-01-26 11:02 PBNC 561 6941360 >> 5616243278 P 10/13 Page 8 of 11 RESEARCHICLINICAL PHARMACOLOGY, (cont.): 2001 MT300, Protocol MT300-301, for Acute Migraine Attacks, Pozen, Phase III, 20Q1 Pregabalin, Protocol 1008-197-158, for Chronic Pain, Pfizer, Phase III. 2001 Zolmitriptan, Protocol 311 CUS/0016, for the Comparison of the Effects of Zomig-ZMT M and Usual Migraine are on Work Loss, Productivity, and Patient Preference, AstraZeneca, Phase III. 2001 SUM40298, for the Treatment of Self -Described and/or Physician -Diagnosed Sinus Headaches that meet International Headache Society Criteria for Migraine Headache, GlaxoSmithKline, Phase III. 2001 PNU 95666E, Protocol 666E -CNS -0075-021, for Early Parkinson's Disease in Patients not Taking Levodopa, Pharmacia, Phase III. 2001 PNU 95666E, Protocol 666E -CNS -0614.001, Pharmacogenomics Flood Sampling Protocol for Sumanirole and Parkinson's Disease, Pharmacia. 2001 Trileptal, Protocol CTR147$Ga230, for Neuropathic Pain due to Diabetic Neuropathy, Novartis, Phase III. 2001 MT100, Protocol MT100-308, for Acute Migraine Attacks, Pozen, Phase III. 2001 Rebif@, Protocol 22982, for the Tolerability of RebifO Injection with and without the use of RebijeCtTM Mini in Relapsing Remitting MS Patients, Serono. Phase 111, 2001 Memantine, Protocol MEM -MD -10, for Mild to Moderate Dementia of the Alzheimer's Type, Forest Laboratories, Phase Ill. 2002 Memantine, Protocol MEM -MD-11, for Mild to Moderate Dementia of the Alzheimer's Type, Forest Laboratories, Phase Ill. 2002 Memantine, Protocol MEM -MD -12, for Mild to Moderate Dementia of the Alzheimer's Type, Forest Laboratories, Phase III, 2002 GW493838, Protocol A1a20005, for Acute Treatment of Migraine, CslaxoSmithKline, Phase 11, 2002 Sumatriptan, Protocol 5UM40299, for Single Moderate or Severe Headache In Adults Diagnosed with Migrainous Disorder. GlaxoSmithKline, Phase III. 2002 Zolmitriptan, Protocol 311 CUS/0022, for Adult Subjects with Migraine, AstraZeneca, Phase III. 2002 Capsaicin Patch, Protocol 0102, for Pain Associated with Postherpetic Neuralgia, Neurogesx, Phase II, 2002 Capsaicin Patch, Protocol 0106, for Post herpetic Neuralgia, Neurogesx, Phase 11. 2002 GW493836, Protocol A1A20004, for Peripheral Neuropathic Pain, GlaxoSmithKline, Phase 11. 2002 Lamotrigine, Protocol NPP30004, for Painful Diabetic Neuropathy, GlaxoSmithKline, Phase Ill. 2003 Lamotrigine, Protocol NPP30006, for Painful Diabetic Neuropathy, GlaxoSmithKline, Phase 111. 2003 Neramexane, Protocol NER-MD-01, for Moderate to Severe Dementia of the Alzheimer's "type, Forest Laboratories, Phase 11, 2003 Neramexane, Protocol NER-MD-02, for Moderate to Severe Dementia of the Alzheimer's Type, Forest Laboratories, Phase it, 2003 Sumanirole, Protocol DA2APD-0075-031, for Early Parkinson's Disease, Pharmacia, Phase III, 2003 Sumanirole, Protocol M/2760/011, for the Parkinson's Disease, Pharmacia, Phase 111 2003 MT300, Protocol MT300-401, for Evaluation of Three Injectable Anti -migraine Drugs, Pozen, Phase IIIb. 2003 NGX-4010, Protocol 0108, for Post herpetic Neuralgia, Neurogesx, Phase 111. 2003 Neramexane, Protocol NER-MD-03, for Moderate to Severe Dementia of the Alzheimer's Type, Forest Laboratories, Phase Ill. 2003 Fidarestat, Protocol SNK-860-201, for Diabetic Polyneuropathy, Sankyo Pharma Development, Phase 11. 2003 Sumatriptan, Protocol SUM30047, for Acute Treatment of Migraine, GlaxoSmithKline, Phase Ill, 2003 GW406381, Protocol CXA20008, for Acute Migraines. GIaxDSmithKline, 2003 GW406381, Protocol CXA20009, for Post herpetic Neuralgia, GlaxoSmithKline, Phase 11. 2003 $R57746A, Protocol EFC2946, for Mild to Moderate Dementia of the Alzheimer's Type, Sanofi -Synthelabo. 2003 Lamotrigine, Protocol NPP30010, Add -On Treatment in $ubjeots with Neuropathic Pain, GlaxoSmithKline, Phase IIL 2003 REN -1654, for Post -herpetic Neuralgia, Renovis, Phase 11 2004 MK -0677, Protocol 030-02, for slowing the Progression of Alzheimer's Disease, Merck & Co., Inc. 2004 Capromorelin, Protocol A2571003, for Fibromyalgia, Pfizer, Inc., Phase 11. 2004 BOTOX, Protocol 191622-066.01, for Post herpetic Neuralgia, Allergan. 2016-01-26 11:02 PBNC 561 6941360 >> 5616243278 P 11/13 Page 9 of 11 RESEARCH/CLINICAL PHARMACOLOGY, (Cont,): 2004 2506POU, Protocol ONO-2506POLJOl0, for Mild to Moderate Alzheimer's Disease, ONO Pharma USA, Inc„ Phase II, 2004 101468/228, Add-on Therapy to L-dopa at Increasing the Time to unset of Dyskinesia in Parkinson's Disease Subjects, GlaxoSmithKline, Phase Illb. 2004 3201, Protocol AS -3201-253, for Diabetic Sensorimotor Polyneuropathy, Dainippon Pharmaceutical Co., Ltd, 2004 Open -Label Pregabalin, Protocol A0081057, for Fibromyalgia, Pfizer Inc. and Affiliates. 2004 Pregabalin, Protocol AQQ81060, for Relief of Pain in painful Diabetic Peripheral Neuropathy, Pfizer Inc. and Affiliates, 2004 Open -Label Pregabalin, Protocol A0081036, for Diabetic Peripheral Neuropathy, Pfizer Inc. and Affiliates. 2004 Pregabalin, Protocol A0081056, for Fibromyalgia, Pfizer Inc, and Affiliates. 2004 Trexima, Protocol 101998, Administration during the Mild Pain Phase of a Migraine, GlaxoSmithKline, 2004 Alzhemed, Protocol CL -758007, for Mild to Moderate Alzheimer's Disease, Neurochem, Inc,, Phase III. 2004 Rizatriptan, Protocol 06800, for Migraine Attack While the Pain is Mild, Merck & Co., Inc, 2004 Xaliproden, Protocol EFC 2945, for Mild to Moderate Dementia of the Alzheimer's type - Sanofi -Synthelabo Research, Phase III. 2004 Neramexane, Protocol NER-MD-03, for Moderate to Severe Dementia of the Alzheimer's Type, Forest Laboratories, 2004 E 2007, Protocol E 2007-A001-210, for Migraine Prophylaxis, Eisai Pharmaceuticals, Phase IIA, 2004 Pregabalin, Protocol AQ081004, for post herpetic Neuralgia, Pfizer Inc., Phase IIB. 2004 Sumatriptan, Protocol #SUM30047, for the Acute Treatment of Migraine. GlaxosmithKflne, Phase Ili. 2004 Rizatriptan, Protocol 065-00, for Migraine Attack while Pain is Mild, Merck, Phase Ill. 2004 CP424,391, Protocol A2571O09-1010, for Fibromyalgia. Pfizer, Phase IL 2004 Reboxetine, Protocol A6061001, for Post herpetic Neuralgia, Pfizer. 2004 Fidarestat, Protocol SNK-860-201, for Diabetic Polyneuropathy, Phase ll, 2004 REN1654, ProtocolREN1654, a 3 Week Active Treatment Extension. Renovis, Phase Il, 2004 EAA-090, Protocol 0912A2 -212 -NA, for Neuropathic Pain associated with Diabetic Neuropathy, Wyeth. 2004 GW406381, ProtocolCXA20009. For Post herpetic Neuralgia. GlaxoSmithKline, Phase II. 2004 Trexima, Protocol MT400-301. For Migraine Headaches. Pozen, Phase 11, 2005 Anandamide, Protocol 2000-202, for the Treatment of Pain Associated with Post herpetic Neuralgia. Kadmus, Phase III, 2005 Rizatriptan, Protocol 071-001072-00, for Menstrual Migraine, Merck Co., Inc, 2005 TAK-128, Protocol 01 -04 -TL -128-003, for Mild to Moderate Diabetic Peripheral Neuropathy, Takeda, Phase ll. 2005 MK -0462, Protocol 071-00, for the Menstrual Migraine, Merck & Co. Inc., Phase III, 2005 Memantine, Protocol MEM -MD -50, for Moderate to Severe Dementia of the Alzheimer's type, Forest Research Institute, Phase 111. 2005 GR43175, Protocol RM2005/00169/00, for Multiple Migraine Attacks, Glaxo$mithKline, 2005 E2007, Protocol E2007-AOQ1-210, for Migraine Prophylaxis, Eisai Pharmaceuticals. 2005 MK -0974, Protocol 004, for the Treatment of Acute Migraine, Merck & Co., Inc., Phase Ilb. 2005 Pregabalin, Protocol A0081077, for Fibromyalgia, Pfizer, Phase III, 2005 MK -0759, Protocol 004-00, for Post herpetic Neuralgia, Merck & Co. Inc., Phase IIA. 2006 TAK-128, Protocol 01 -05 -TL -128-006, for Mild to Moderate Diabetic Peripheral Neuropathy, Takeda, Phase 11. 2006 DVS SR, Protocol 3151A5 -322 -US, for Pain Associated with Diabetic Peripheral Neuropathy, Wyeth Pharmaceuticals, Phase 111. 2006 DVS SR, Protocol 3161A4 -327 -US, for Fibromyalgia Syndrome, Wyeth Pharmaceuticals, Phase Ill. 2006 Topiramate, Protocol CAPSS-381, to Prevent Transformation of Episodic Migraine, Ortho -McNeil Pharmaceutical, Inc., Phase IV, 2006 PRO -513, Protocol PRO -513301, for Migraine Attacks, ProEthic Pharmaceuticals, Phase Ill. 2016-01-26 11:02 PBNC 561 6941360 » 5616243278 P 12/13 Page 10 of 11 RESEARCH/CLINICAL PHARMACOLOGY cont. 2006 Reboxetine, Protocol A6061026, for Post herpetic Neuralgia, Pfizer, Phase Il, 2006 Mirapex, Protocol 248.595, for New Onset Parkinson's Disease, Boehringer Ingelheim, Phase IV, 2006 Stalevo@, Protocol CELC200AUS11, for Parkinson's disease with End -of -Dose wearing off. Novartis, Phase IV, 2006 Quetiapine SR, Study Code 01448C00005, for Major Depressive, Astra Zeneca, Phase III, 2006 AlzhemedW, Protocol CL -758017, for Alzheimer's Disease, Neurochem, Phase Ili. 2006 Prochlorperazine, Protocol AMD0-001-202, for Migraine Headaches, Alexza pharmaceuticals, Phase 11. 2006 E2007, Protocol E2007 -A001-902, for Parkinson's Disease Patients with Motor Fluctuations, Eisai Medical Research, Phase III. 2006 AVE1625, Protocol ACT10019, for Mild to Moderate Alzheimer's Disease, Sanofi Aventis, Phase 11. 2006 MK -0249, Protocol 011-00, For the Symptomatic Treatment of Alzheimer's Disease, Merck, Phase IIA. 2006 DVS SR, Protocol 3151A5 -925 -US, for Pain Associated with Diabetic Peripheral Neuropathy, Wyeth Pharmaceuticals, Phase III. 2006 Rlmonabant, CRESCENDO Protocol EFC5826, for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering Risk Factors, Sanofi Aventis, Phase it/ill. 2006 [$, 8]-Reboxetine, Protocol A6061029, for Post herpetic Neuralgia, Pfizer, Phase ll. 2006 Pregaballn, Protocol A0081078, for Fibromyalgia, Pfizer, Phase 111, 2007 TAK-583, Protocol 01 -06 -TL -583-006, for Mild to Moderate Diabetic Neuropathy, Takeda Global Research & Development Center, Inc., Phase 11. 2007 MK -0974, Protocol 011-02, for Migraine with or without Aura, Merck & Co., Inc., Phase Ill. 2007 MK -0974, Protocol 012-02, for the Long Term Treatment of Acute Migraine with or without Aura, Merck & Co., Inc., Phase 111, 2007 Lacosamide, Protocol 8P906, for Migraine Prophylaxis, Schwarz Blosclenees, Inc., Phase Il. 2007 Rotigotine, Protocol SP888, for Fibromyalgia Syndrome, Schwarz Biosciences, Inc., Phase IIA. 2007 E2020, Protocol E2020 -G000-326, for Moderate to Severe Alzheimer's Disease, Eisai, Phase 111, 2007 Loxapine, Protocol AMDC-104-201, for Migraine Headache, Alexza Pharmaceuticals, Phase 11, 2007 E2007, Protocol E2007-Cap00-227, for Painful Diabetic Neuropathy, Eisai Medical Research Inc., Phase Illilt. 2007 ABT -089, Protocol M06-876, for Alzheimer's Disease, Abbott Laboratories, Phase 11, 2007 V950, Protocol 001-01, for Alzheimer's disease, Merck & Co., Inc., Phase 1. 2007 RN624, ProtocolA4091005, for Post -herpetic Neuralgia. Pfizer, Phase Iia. 2007 E2007, Protocol E2007 -G000-303, for Parkinson's Disease Patients with Motor Fluctuations, Eisai, Phase III. 2008 ABT -894, Protocol M06-850, for Diabetic Neuropathic Pain, Abbott Laboratories, Phase 11. 2008 AAB 001, ELN115727, Protocol ELN115727-301, for Mild to Moderate Alzheimer's Disease, Elan Pharmaceuticals, Inc., Phase Ill. 2008 AAB-001, ELN115727. Protocol ELN 115727-302, for Mild to Moderate Alzheimer's Disease, Elan Pharmaceuticals, Inc,, Phase ill. 2008 Perampanel (E2007), Protocol E2007 -A01-218, for Post -herpetic Neuralgia, Eisai Medical Research Inc„ Phase 11. 2008 SMS -741672, Protocol MBI 14006, for Diabetic Neuropathic Pain. Bristol -Meyers Squibb (BMS), Phase IIA. 2008 MK -0974, Protocol 031-03, for Migraine with or without Aura. Merck & Co. Inc., Phase III. 2008 Pramipexole ER, Protocol 248.637, for Fibrotriyalgia, Boehringer Ingelheim. 2008 MK -3207, Protocol 005-00, for Acute Migraine, Merck & Co., Inc., Phase IIB, 2008 MK 0974, Protocol 049, for Migraine Prophylaxis in Patients with Episodic Migraine. Merck & Co., Inc., Phase IIA, 2008 E2020, Protocol E2020 -G000-328, for Moderate to Severe Alzheimer's disease, Eisai, Phase Ill. 2008 E2007 (Perampanel), Protocol E2007 -G000-228, for Painful Diabetic Neuropathy or Post -herpetic Neuralgia, Eisai, Phase II/Ili, 2008 NPI 01, Protocol NPI 01-007, for Acute Migraine, NuPathe, Phase 111. 2009 Loxapine, Protocol AMD0104-202, for Migraines, Alexza Pharmaceuticals, Inc., Phase IL 2009 Rizatriptan, Protocol 085-00, for Migraine Prophylaxis, Merck, Phase IV. 2016-01-26 11:03 PBNC 561 6941360 >> 5616243278 P 13/13 Page 11 of 11 RESEARCH/CLINICAL PHARMACOLOGY, (cont,): 2009 LY451395, Protocol H6N-MC-LEAD(a), for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's disease, Eli Lilly, Phase II. 2009 ABT -089, Protocol M10-745, for Mild to Moderate Alzheimer's disease, Abbott Laboratories, Phase 11, 2009 AZD2066, Protocol D0475C00016, to evaluate the analgesic efficacy of 28 days oral administration, AstraZeneca, Phase IIA, 2009 Ranirestat, Protocol AS3201-Gp00-291, for Mild to Moderate Diabetic Sensorimotor Polyneuropathy, Eisai Limited, Phase 11/111. 2009 JNJ-42160443, Protocol 421604431NIPP2001, for post -herpetic Neuralgia and Post Traumatic Neuralgia, Johnson & Johnson, Phase II. 2009 JNJ-42160443, Protocol 42160443NPP2002, for Diabetic Painful Neuropathy, Johnson & Johnson, Phase 11, 2009 Bapineuzumab, Protocol 3133K1-3001, for Mild to Moderate Alzheimer's Disease, Wyeth Pharmaceuticals, Inc., Phase III. 2010 Bapineuzumab, Protocol ELN115727-351, for Alzheimer's Disease, JANSSEN Alzheimer Immunotherapy, Phase III. 2010 Tapentadol ER, Protocol R331333PAI3028, for Chronic, Painful Diabetic Peripheral Neuropathy, Johnson & Johnson, Phase III. 2010 PF -04383119, Protocol A4091031, for Diabetic Peripheral Neuropathy, Pfizer, Phase IL 2010 Preladenant, Protocol P04938, for Parkinson's disease, Schering-Plough, Phase 111. 2010 Preladenant, Protocol P06153, for Parkinson's disease, Schering-Plough, Phase 111. 2011 Bapineuzumab, Protocol 3133K1-3000 (Wyeth) / Protocol B2521001 (Pfizer). Mild to moderate Alzheimer's disease for Apolipoprotein E4 Non -carriers. Wyeth/Pfizer, Phase III. 2011 Bapineuzumab, Protocol 31133K1-3003 / 82521004, Open label study for subjects who completed the 3001 study. Wyeth/ Pfizer, Phase III. 2011 Pregabalin, Protocol A0081242. In the treatment of patients with inadequately treated painful diabetic neuropathy. Pfizer, Phase IIIb. 2011 GRALISE (gabapentin) Protocol 81-0067, For the treatment Post herpetic Neuralgia in clinical practice DepoMed, Inc., Phase IV, 2012 MK6096, Protocol 020-00. Migraine prophylaxis for episodic migraine. Merck, Phase Ila, 2012 Pregabalin, Protocol A0081268. Diabetic neuropathy, subjects treated with NSAIDS for comorbid condition. Pfizer, Phase Illb. 2012 BMS -241027. Protocol CN167003, Mild Alzheimer's disease, Bristol Meyers Squibb, Phase 1. 2012 SAR292833. Protocol ACT11917. Neuropathic pain, Sanofi. Phase 11. 2012 VM202. Protocol VMDN-002/ C. Diabetic Neuropathy. ViroMed Biopharma, Phase Il. 2012 MK1602. Protocol 006-00. Migraine Headache. Merck. Phase Ilb. 2012 V116517. Protocol VND2002, Chronic pain due to Post herpetic Neuralgia, Purdue Pharma. Phase 11 2012 Rotigotine, Protocol PDO005. Parkinson's Disease relates Apathy, Motor Symptoms & Mood. Phase IV, UCB Biosciences GmbH 2013 Panadol Extra, RH01649. Episodic Tension Type Headache, Phase 111. GlaxosmithKline 2013 13AN 2401. Protocol BAN2401-G000-201. Early Alzheimer's disease. Eisai. Phase 11, 2013 MK -8931. Protocol MK8931-017. Mild to moderate Alzheimer's disease, Merck Phase 11/111. 2013 ELND005. Protocol ELN0005-AG201, Agitation and Aggression in moderate to severe Alzheimer's disease. Elan Pharmaceuticals Inc. Phase 11. 2013 AMG 334. Protocol 20120178. Episodic Migraine prevention. Amgen Inc, Phase 11, 2013 MK -$931, Protocol MK -8931-019, Prodromal AD. Phase III, Merck 2014 AMG 334. Protocol 20120295. Chronic Migraine Prevention, Phase Il. Amgen Inc, 2014 LuAE58054, Protocol 14862A. Mild to Moderate Alzheimer's disease treated with Donepezil. Lundbeck, Phase 111.